ASX-listed biotech firm CSL has issued a profit warning and announced approximately US$5 billion ($8.4b) in impairments. This move is attributed to lower prices for key products and the effects of the conflict in the Middle East. The company's shares have halved in value over the past year. Full-year results, expected in August, are projected to show declines in both profits and revenue. The announcement follows a challenging period for CSL, impacting its market performance.